Loading patent…
AssigneeThe University of North Carolina at Chapel Hill
InventorsWendell Gray Yarbrough, Natalia Isaeva, Travis Parke Schrank
Estimating the term…
This disclosure provides a method for evaluating the prognosis of a head and neck cancer patient. The head and neck cancer may be human papillomavirus positive (HPV+) and originate in the upper aerodigestive tract (e.g. oropharynx, nasopharynx, nasal cavity, sinus, or hypopharynx). In addition, the disclosure provides a method for predicting a response of a head and neck cancer patient to a selected treatment. The disclosure also provides a method for generating an improved head and neck cancer biomarker signature for patient prognosis and uses thereof.
A method for evaluating the prognosis of a human papilloma virus (HPV) associated head and neck cancer patient, comprising detecting defects in nucleic acids encoding genes, or their expression products, of TRAF3, CYLD, TRAF2, MYD88, NFKBIA, TNFAIP3, TRAF6, BIRC2, BIRC3, and MAP3K14 in a sample from the patient, normalized against a reference set of nucleic acids encoding genes, or their expression products, in the sample, wherein defects in the nucleic acids or their expression products is indicative of prognosis, thereby evaluating the prognosis of the head and neck cancer patient.
The method of claim 3, wherein the head and neck cancer is an oropharyngeal squamous cell carcinoma (OPSCC).
(canceled)
(canceled)
The method of claim 10, wherein the method is used to develop a treatment strategy for the head and neck cancer patient.
A method for predicting a response of a human papilloma virus (HPV) associated head and neck cancer patient to a selected treatment, comprising detecting defects in nucleic acids encoding genes, or their expression products, of TRAF3, CYLD, TRAF2, MYD88, NFKBIA, TNFAIP3, TRAF6, BIRC2, BIRC3, and MAP3K14 in a sample from the patient, normalized against a reference set of nucleic acids encoding genes, or their expression products, in the sample, wherein defects in the nucleic acids, or their expression products, is indicative of a positive treatment response, thereby predicting the response of the head and cancer patient to the treatment.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for evaluating the prognosis of a human papilloma virus (HPV) associated head and neck cancer patient, comprising measuring mRNA expression of MGAT3, STAR, VCAM1, RAB42, NFE2L3, FGF2, ABCA3, RNF165, PKDCC, and ZBTB46 in a sample comprising a cancer cell from the patient, normalized against the expression levels of all RNA transcripts in the sample or a reference set of mRNA expression levels, wherein the mRNA expression levels of MGAT3, STAR, VCAM1, RAB42, NFE2L3, FGF2, ABCA3, RNF165, PKDCC, and ZBTB46 are indicative of NF-kB activity, thereby evaluating the prognosis of the head and neck cancer patient.
(canceled)
(canceled)
(canceled)
An isolated and purified probe for specifically detecting defects in (a) nucleic acids encoding CYLD mutation N300S or D618A, or (b) their expression products.
Dependencies are inferred from the claim text.